Pumitamig pivotal trials come in pairs
Bristol will test the bispecific in two new lung indications.
Cardiff goes south again
The latest onvansertib data, and an abrupt CEO departure, spook investors.
A first test of OnKure’s mutant-specific gamble
A phase 1 study of OKI-219 reads out imminently.
ImmuneOnco takes a second project pivotal
The group’s CD47 x CD20 fusion protein will soon go into a Chinese phase 3.
HengRui spreads its SERD
New pivotal trials of HRS-8080 are planned in first-line and adjuvant breast cancer.
Huabo goes pivotal with bispecific VEGF trap
The company takes a PD-L1 x VEGF asset into phase 3.
Two more companies try to outdo Rybrevant
After Genmab’s exit two more ADCs enter human trials.
Novartis perseveres with pelabresib
A new phase 3, Manifest-3, will start in April to support US filing.
